A NEW type of antidepressant
may bring instant relief to people
suffering serious suicidal thoughts.
US researchers say the chemical
known as “CGP3466B” works in a
similar way to ketamine but with
much fewer negative side effects.
It will take several years to trial
CGP3466B as a human antidepressant,
but the compound,
developed late last century by
pharmaceutical giant Novartis has
been found to be non-addictive and
non-toxic.
New research on the chemical is
being led by neuroscientists from
Johns Hopkins Medicine.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 16
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.